Anavex Life Sciences Corp (AVXL)

[nidan7500]

"Positive results for Sarepta Therapeutics Inc.’s new Duchenne muscular dystrophy drug in an early/mid-stage trial have sparked hopes for accelerated approval of the drug and propelled the company’s stock up as much as 14%. It’s also sure to spur comparisons to Sarepta’s SRPT, +13.75% last drug approval. Eteplirsen was the first U.S. drug approved for DMD, a rare degenerative and often deadly disease, but its September approval was marred by significant controversy and a remarkable level of open disagreement at the Food and Drug Administration. The results for the treatment golodirsen “will ignite much debate about the quality of the data and whether it will satisfy the FDA, reminiscent of pre-approval"

Cannot happen soon enough.